Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
CLEVELAND, Feb. 14, 2017 -- Athersys, Inc. (Nasdaq:ATHX) will release its year-end 2016 financial results at approximately 4:00 PM Eastern Time on Thursday, March 9, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | March 9, 2017 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | (800) 273-1254 |
| Telephone access: International | (973) 638-3440 |
| Access code | 73151585 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on March 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 73151585.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected] David Schull Russo Partners, LLC 12 West 27th Street, 4th Floor New York, NY 10001 Tel: (212) 845-4271 [email protected]
